Pharmaceutical giant Pfizer
is conducting a 1,200-strong
patient clinical trial in the United
States to test if consumers
taking a nonprescription Lipitor
(atorvastatin) will make the right
decisions around the results of
their own blood tests measuring
their cholesterol.
The trial, recruiting patients
through more than 35 US
pharmacies, is planned for
completion by the end of 2014.
Doctor groups have expressed
concerns that patients may be
underdosed given that only the
10mg dose will be trialled and
that side effects such as muscle
pain may not be recognised as
associated with the therapy.
Pfizer told the Wall Street Journal
that an over-the-counter Lipitor
would help close a “treatment gap”
for people at risk of heart attacks
and strokes who don’t currently
take a statin, potentially generating
savings for the healthcare system
by preventing more costly problems
later in life.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Mar 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.